Drugs in ATC Class J05AB

Up to Top Level ATC Classes

Up to J - Antiinfectives for systemic use

Up to J05 - ANTIVIRALS FOR SYSTEMIC USE

Up to J05A - DIRECT ACTING ANTIVIRALS

Drugs in ATC Class: J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Tradename	Generic Name
STOXIL	idoxuridine
DENDRID	idoxuridine
HERPLEX	idoxuridine
VIRA-A	vidarabine

ATC J05AB nucleosides and nucleotides (excl. reverse transcriptase inhibitors) market dynamics and patent landscape

Last updated: June 8, 2026

What is the ATC J05AB market size and growth profile for nucleosides and nucleotides?

Executive summary: ATC J05AB covers a set of indirect-acting antiviral nucleoside/nucleotide analogs that target viral polymerases across hepatitis B and herpesvirus infections. The market dynamics are dominated by (1) generics entry pressure after primary patent and regulatory exclusivity expiry, (2) evergreening via reformulations and prodrug/manufacturing variants, and (3) portfolio competition where multiple nucleoside/nucleotide drugs share similar prescribing pathways but different resistance and resistance testing requirements.

Demand drivers and payer behavior

• Hepatitis B (HBV) is the largest revenue pool for J05AB nucleosides/nucleotides, with treatment duration often long-term and driven by guideline-based “suppress or stop” strategies.
• Herpesvirus (HSV/VZV) utilization is typically episodic or maintenance, but long-term suppressive therapy increases lifetime exposure.
• Payer constraints are strongest where multiple nucleoside options exist and where me-too dosing does not change monitoring requirements.

Competitive structure (what matters commercially)

• Top-line winners tend to have:
  • durable resistance profiles (or lower breakthrough rates),
  • a resistance monitoring ecosystem that reduces physician reluctance,
  • and patent estates that block direct generic substitution in key jurisdictions.
• Margins compress fast after generic entry for molecules with early-originator timelines unless the originator maintains formulation or manufacturing IP that creates FDA or EMA substitutability barriers.

Which molecules are in ATC J05AB and how does the IP landscape differ by antiviral target?

Executive summary: J05AB’s patent risk is not uniform. HBV nucleos/tides tend to have layered protection across active ingredient, prodrug conversion, and manufacturing. Herpes nucleosides show higher variance by molecule, often with fewer treatment-limiting endpoints but significant resistance-driven switching.

J05AB molecule map by viral family (practical framing)

• HBV polymerase-targeting nucleos(t)ides
  • Typical patent themes: prodrug rationale, phosphorylation kinetics, and manufacturing purification/process control.
• HSV/VZV polymerase-targeting nucleosides
  • Typical patent themes: prodrug chemistry, tissue activation profiles, and specific crystalline forms.

Resistance and switching dynamics create patent value

• Patent estates are reinforced by clinical need for resistance management.
• Where resistance testing is common, clinicians keep patients on a stable regimen longer, extending de facto market exclusivity even after legal exclusivity ends.

How many patents cover each J05AB active ingredient and what types dominate (compound, formulation, method of use, process)?

Executive summary: J05AB estates are typically dominated by:

1. composition-of-matter (original nucleoside/nucleotide),
2. prodrug and salt/crystal form claims,
3. process/manufacturing claims (impurities, intermediates, stereochemistry control),
4. formulation claims (fixed-dose combinations where applicable, film coat, solid-state forms),
5. method-of-use and resistance/combination regimens, especially where later clinical practice broadens label scope.

Dominant IP claim categories in nucleosides/nucleotides

• Composition of matter: active ingredient, tautomers, stereoisomers, salts, solvates.
• Solid-state forms: polymorphs, hydrates, amorphous forms, particle size ranges.
• Process claims: synthetic intermediates, purification steps, crystallization parameters, impurity control.
• Formulation claims: tablet/capsule compositions, excipient systems, controlled release (when present).
• Method of use: HBV disease stage subsets, combination regimens, pediatric use expansions.

When do key J05AB products lose patent exclusivity in the US and Europe?

Executive summary: Loss of exclusivity for J05AB products occurs on two tracks:

• legal patent expiry (20-year filing term plus specific patent term adjustments where applicable),
• regulatory exclusivity (US non-patent exclusivity and EU marketing exclusivity for data protection where relevant).

How exclusivity typically cascades

• Primary compound patents expire first.
• Then courts and patent offices assess whether secondary patents (formulations/process) still prevent generic substitution.
• In HBV, continued patentability of manufacturing processes can delay “at-risk” launches.

Timeline archetypes observed in nucleos/tides

• HBV originators: compound patents + later crystal form/process patents often extend the practical “launch window.”
• Herpes nucleosides: less uniform, but solid-state/process patents frequently control the generic substitution path.

What is the Orange Book status of major J05AB nucleosides/nucleotides and where are the Hatch-Waxman bottlenecks?

Executive summary: The Orange Book governs US generic entry risk. For J05AB, Hatch-Waxman risk concentrates in:

• whether the ANDA is forced to file Paragraph IV to secondary patents,
• whether patents are listed as use or dosage/form or drug substance (impacting what the generic must address),
• and whether originators maintain enough enforceable listings to block approval.

Featured snippet answer

• Orange Book bottleneck for J05AB is usually secondary patents that remain listed and asserted, rather than the original compound claims.

What to screen on Orange Book for J05AB

• Patent type: drug substance vs drug product vs method-of-use.
• Expiry date sequencing: identify the next non-expired patent in the “approval-critical” category.
• Litigation posture: whether the patent has a history of co-filed ANDA challenges or settlements.

How do Paragraph IV challenges and settlements shape generic launch timing for J05AB?

Executive summary: For nucleos/tides, Paragraph IV litigation patterns are consistent:

• Generics file ANDAs “at risk” once the next listed patent is challengeable.
• Originators often pursue early dismissal, injunction motions, and trial strategy around obviousness or noninfringement.
• Settlements frequently shift launch timing by creating a “license-like” delay while permitting design-around testing.

Business impact

• The economic value of settlement hinges on the time to first commercial generic relative to:
  • physician switching inertia,
  • payer formulary replacement cycles,
  • and contract lead times.

At-risk launch triggers

• If the originator’s remaining asserted patents are weak on novelty or are narrow to non-commercial embodiments, generics accelerate entry.
• If asserted patents cover generic-relevant formulations or drug substance process constraints, originators negotiate longer delays.

Which patent types create the highest barriers for generic substitution of J05AB drugs?

Executive summary: For J05AB nucleos/tides, the most substitutability-resistant patents are typically:

• solid-state form and crystalline form patents that limit whether the generic drug is “equivalent” in claimed parameters,
• process/manufacturing patents tied to drug substance impurities and controlled parameters,
• and method-of-use patents that constrain label-based interchangeability.

Practical “barrier ranking”

1. Drug product/dosage-form limitations (if claims map to compendial excipients or process-dependent performance).
2. Crystalline form or particle size patents (when generics must demonstrate non-infringement by characterization).
3. Process patents (where infringement hinges on generic synthesis details and discovery access).
4. Method-of-use patents (less likely to block approval outright, more likely to affect launch labeling strategy).

How does patent landscape differ for HBV nucleos(t)ides vs herpes nucleosides within J05AB?

Executive summary: HBV within J05AB typically shows more layered, long-tail patent protection because therapy is prolonged and resistance management creates a durable commercial window. Herpes nucleosides can also have long estates, but the substitution and switching dynamics differ due to shorter treatment horizons for many patients.

HBV: resistance-driven label durability

• Originators often expand label language in ways that preserve commercial relevance even after primary claims expire.
• Combination and sequencing strategies can support method-of-use claims.

Herpes: formulation and solid-state control

• Generic entrants often need to demonstrate bioequivalence while avoiding protected solid-state forms or manufacturing impurity profiles.

What formulations and drug delivery patents protect J05AB products (and what design-arounds exist)?

Executive summary: J05AB formulation IP tends to cluster around:

• specific tablet/capsule compositions,
• solid-state form control,
• and manufacturing-related purity/impurity specifications. Design-arounds typically target:
• different polymorph/crystal form generation,
• alternative excipient systems that remain bioequivalent,
• and process changes that avoid claimed intermediates.

Common formulation IP levers

• Polymorph/hydrate patents that are defeated only by showing a different form.
• Particle size distribution and milling parameters, which affect dissolution and can determine whether the generic falls within claim bounds.

What method-of-use patents for J05AB affect labeling and clinical adoption?

Executive summary: Method-of-use patents can affect whether generics can market quickly with the originator’s exact indication language, even when they win on composition and drug product claims.

Where method-of-use protection matters most

• Expanded HBV subsets tied to baseline biomarkers or prior treatment histories.
• Combination therapy regimens for viral suppression where label language is narrow.

Do J05AB drugs face biosimilar-like risks, or are they strictly small-molecule generics?

Executive summary: J05AB covers small-molecule nucleosides and nucleotides, not biologics. The risk profile is therefore Hatch-Waxman and Section viii/ANDA-type pathways in the US and generic/parallel legal pathways in the EU, not biosimilar exclusivity.

What replaces biosimilar risk

• Compendial interchangeability and label carve-outs due to method-of-use patents.
• Litigation risk tied to drug substance process and solid-state form.

Which companies compete in J05AB after exclusivity and what is the typical generic entry playbook?

Executive summary: Post-exclusivity competition usually features:

• large US ANDA filers (for high-volume HBV and herpes drugs),
• regional EU generics at scale,
• and “authorized generic” strategies via licensing where originators monetize settlements.

Generic entry playbook for nucleos/tides

• Identify “approval-critical” Orange Book patents (drug substance vs drug product vs use).
• Select strategy: Paragraph IV challenge or section viii carve-out pathway if applicable.
• Prepare infringement defense around:
  • polymorph characterization,
  • impurity profiles and process mapping,
  • and pharmacokinetic proof of bioequivalence.

What is the strongest patent estate scenario within J05AB, and where is litigation most likely?

Executive summary: Strong estates cluster where originators keep narrow but enforceable claims on:

• solid-state forms and drug product,
• and manufacturing processes that define non-obvious impurity handling.

Litigation is most likely where:

• multiple generics file simultaneously,
• settlement terms materially change launch economics,
• and originators have a history of enforcing secondary patents.

Key Takeaways

• J05AB is dominated by HBV and herpes nucleoside/nucleotide small molecules, with clinical resistance management extending real-world therapy continuity.
• Patent leverage is typically secondary: solid-state form, process, and drug product claims are more likely to block generic substitution than primary compound patents.
• US launch timing is governed by Orange Book listings and Paragraph IV outcomes, with settlement agreements often used to manage entry delay.
• EU competition is shaped by data/market exclusivity combined with patent enforcement, with generic entry timing sensitive to enforceability of crystalline form and manufacturing-process patents.

FAQs

1. Which J05AB patents are most frequently asserted in Paragraph IV ANDA litigation: compound, formulation, or process?
2. What Orange Book patent listing categories most constrain J05AB generic approvals?
3. How do polymorph and particle size patents affect the ability of generics to launch nucleoside/nucleotide products?
4. What settlement structures are typical in J05AB exclusivity disputes, and how do they impact first commercial generic timing?
5. What HBV label expansions increase the value of method-of-use patents for J05AB nucleos(t)ides?

References

1. FDA. “Drugs@FDA: FDA Approved Drug Products.” U.S. Food and Drug Administration.
2. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
3. European Medicines Agency (EMA). “Human medicines: Marketing authorisation.” European Medicines Agency.